|
IKNA | Imagenebio, Inc. |
|
|
IKNA | Imagenebio, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 1.94 |
| Leverage | 13.08% |
| Market Cap | $ 71.9m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -45.0m |
| Margin | -490.95% |
Ikena Oncology, Inc., a targeted oncology company, is focused on developing new cancer therapies that target key signaling pathways that drive cancer formation and spread. The company is headquartered in Boston, Massachusetts.